Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Annovis Bio Inc ANVS

Healthcare Biotechnology
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced... see more

Recent & Breaking News (NYSE:ANVS)

ANNOVIS BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

PR Newswire April 3, 2023

ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD(TM) 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES

PR Newswire March 22, 2023

Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease

PR Newswire February 8, 2023

Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

PR Newswire February 1, 2023

ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE

PR Newswire January 25, 2023

Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team

PR Newswire January 6, 2023

Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

PR Newswire November 8, 2022

Annovis Bio to Present at the 2022 ThinkEquity Investor Conference

PR Newswire October 20, 2022

Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

PR Newswire October 11, 2022

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease

PR Newswire October 6, 2022

Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference

PR Newswire September 29, 2022

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

PR Newswire September 13, 2022

Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders

PR Newswire September 8, 2022

Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

PR Newswire August 29, 2022

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease

PR Newswire August 24, 2022

Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update

PR Newswire August 8, 2022

Annovis Bio to Participate on Alzheimer's Association International Conference Panel

PR Newswire August 1, 2022

Annovis Bio to Present at the Alzheimer's Association International Conference

PR Newswire July 14, 2022

Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease

PR Newswire July 7, 2022

Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections

PR Newswire June 9, 2022